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| Evidence review
Members of the Task Force were asked to perform a detailed literature review, weigh the strength of evidence for or against a particular treatment or procedure, and include estimates of expected health outcomes for which data exist. Patient-specific modifiers, comorbidities, and issues of patient preference that might influence the choice of particular tests or therapies are considered, as are frequency of follow-up and cost-effectiveness. In controversial areas, or with regard to issues without evidence other than usual clinical practice, a consensus was achieved by agreement of the expert panel after thorough deliberations. This document was prepared by the Task Force with representation from EHRA, HRS, APHRS, and LAHRS. The document was peer-reviewed by official external reviewers representing EHRA, HRS, APHRS, and LAHRS.
Consensus statements are evidence-based and derived primarily from published data or determined through consensus opinion if data are not available. Current systems of ranking level of evidence are becoming complicated in a way that their practical utility might be compromised. 1 In contrast to guidelines, we opted for an easier and user-friendly system of ranking using "coloured hearts" that should allow physicians to easily assess the current status of the evidence and consequent guidance (Table 1 ). This EHRA grading of consensus statements does not have separate definitions of the level of evidence. This categorization, used for consensus statements, must not be considered as directly similar to that used for official society guideline recommendations, which apply a classification (Class I-III) and level of evidence (A, B, and C) to recommendations used in official guidelines.
Thus, a green heart indicates a "should do this" consensus statement or indicated treatment or procedure that is based on at least one randomized trial, or is supported by strong observational evidence that it is beneficial and effective. A yellow heart indicates general agreement and/or scientific evidence favouring a "may do this" statement or the usefulness/efficacy of a treatment or procedure. A "yellow heart" symbol may be supported by randomized trials based on a small number of patients or which is not widely applicable. Treatment strategies for which there is scientific evidence of potential harm and should not be used ("do not do this") are indicated by a red heart.
Finally, this is a consensus document that includes evidence and expert opinions from several countries. The pharmacological and
T A B L E 1 Scientific rationale of recommendations a

Definitions related to a treatment or procedure Consensus statement instruction Symbol
Scientific evidence that a treatment or procedure is beneficial and effective. Requires at least one randomized trial, or is supported by strong observational evidence and authors' consensus (as indicated by an asterisk)
"Should do this"
General agreement and/or scientific evidence favour the usefulness/efficacy of a treatment or procedure. May be supported by randomized trials based on a small number of patients or which is not widely applicable "May do this"
Scientific evidence or general agreement not to use or recommend a treatment or procedure "Do not do this" a This categorization for our consensus document should not be considered as being directly similar to that used for official society guideline recommendations which apply a classification (I-III) and level of evidence (A, B, and C) to recommendations.
non-pharmacological antiarrhythmic approaches discussed may, therefore, include drugs that do not have the approval of governmental regulatory agencies in all countries.
| Relationships with industry and other conflicts
All members of the writing group, as well as reviewers, have disclosed any potential conflict of interest in detail and is available in Appendix S1-S3.
All recommendations were voted upon by the writing committee independently and reached ≥80% consensus for inclusion in recommendations tables. Each partner society officially reviewed the document and all reviewer comments were addressed. Table 2 and include many of the risk factors included in stroke risk scores in AF.
| METHODS FOR ASSESSMENT OF COGNITIVE FUNCTION
Impairments of cognitive function often can be subtle and insidious, presenting as missed appointments, mislaying objects, or minor problems at work or home, which are often attributed to stress, age, or pressure of work. Any difference in appearance, behaviour or functioning reported by the patient or the family should alert the physician to the need for a formal assessment. The aim of this assessment is to examine higher cortical functions (attention, orientation, memory, language, praxis, and executive function) from patient narrative, collateral information from families, clinical examination, and standardized tests of cognitive function. 30 For assessment of cognitive impairment, a combination of tools and methods are used (Table 3) .
During the assessment, particular attention needs to be paid to aspects such as vagueness with dates and events, repetition, inap- A list of cognitive assessment tools is provided in Table 4 . Several tools are available for cognitive assessment, but there is no consensus on a preferred approach. The choice of tool should vary with the purpose of testing and other factors, such as availability, familiarity, and feasibility. 31 Common assessment tools are the two- 
| ROLE OF IMAGING
Brain imaging studies can identify vascular disease as a cause of dementia. In an autopsy study of patients with dementia, pathologic diagnoses implicated vascular disease in about 25% of subjects, half of whom had pure vascular disease. 52 The three main causes of vascular cognitive impairment are large vessel strokes, small vessel disease (SVD), and micro-haemorrhages. The preferred imaging modality, magnetic resonance imaging (MRI), has high specificity and sensitivity for detecting these changes and is an important adjunct to clinical and psychometric assessments. Physical activity Increased physical activity is associated with lower risk of general dementia, Alzheimer's dementia, and VaD risk, which was attenuated with further adjustment for baseline cognitive, psychosocial, and vascular factors. Review reported that seven out of eight studies found an association between increased physical activity and lower risk of cognitive decline 12 Body mass index U-shaped association between body mass index and dementia, with dementia risk higher in individuals who were obese or underweight 13 Smoking Meta-analysis reported that current smokers have higher risk of cognitive decline and dementia over follow-up, than non-smokers or former smokers 14 Social support and networks Compared with small social networks, larger social networks were associated with a lower risk of incident dementia over time. 15 
Cardiovascular risk factors
Blood pressure Higher mid-life blood pressure was associated with higher dementia risk 16 and cognitive decline 17 Blood glucose Diabetes was associated with increased dementia risk 18 and cognitive decline 19 
Lipids
Higher total serum cholesterol was associated with higher VaD and AD risk 20, 21 Clinical cardiovascular or cerebrovascular disease Stroke Stroke is associated with increased dementia risk 22, 23 AF AF is associated with increased dementia risk 24, 25 Vascular/peripheral arterial disease Carotid arterial disease is associated with incident dementia risk and cognitive decline 26, 27 Lower ankle brachial index is associated with increased dementia risk 28 Sleep apnoea Sleep-disordered breathing is associated with an increased risk of cognitive impairment and a small worsening in executive function. telemetry monitoring was associated with lower cognitive function.
Another small cross-sectional study reported that cognitive performance did not significantly differ by AF burden, but the number of subclinical cerebral ischaemia areas was higher in individuals with persistent compared with paroxysmal AF. 56 More conclusive understanding of the relation of AF burden to cognitive decline and dementia will require larger and longitudinal studies. The relation between AF type and cognitive impairment and dementia is further complicated by the sometimes arbitrary definition of the AF type in the individual patient.
Unfortunately there are no randomized data examining the efficacy of therapies and in particular of individualized management to prevent dementia in individuals with AF. 57 Of interest, the Framingham Heart Study has examined temporal trends in the incidence of dementia and noted that the risk of dementia associated with AF declined over three decades (1970s to the early 2010s). 58 One speculation is that improved anticoagulation and treatment of risk factors were responsible for the declining incidence of dementia in individuals with AF. Another piece of inferential evidence, supporting the benefit of preventing stroke as a strategy to prevent dementia in individuals with AF, are observational meta-analyses (Table 6 ). In individuals with AF but without stroke at baseline the risk of dementia and cognitive decline is more modest [relative risk (RR) 1.37, 95% confidence interval (CI) 1.08-1.73] than in individuals with both AF and a history of stroke (RR 2.7, 95% CI: 1.82-4.00).
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Systemic anticoagulation remains the cornerstone of stroke prevention treatment. By meta-analysis, adjusted-dose warfarin is associated with a 64% (95% CI: 49-74%) significantly lower risk of stroke (Table 7) , whereas aspirin alone was associated with a 19% (95% CI:
À1 to 35%) non-significant lower stroke risk. 59 In studies comparing warfarin and aspirin, warfarin was associated with a 38% (95% CI:
18-52%) stroke reduction, when compared with aspirin alone.
59
A meta-analysis of the four randomized trials comparing the non- cognitive impairment share common risk factors, including advanced age, diabetes, hypertension, sleep apnoea, and chronic heart failure.
Moreover, data have demonstrated a significant (34%) increase in the risk of cognitive impairment in patients with AF in the absence of clinical stroke, even after adjustment for shared risk factors. 25, 64 Thus, additional mechanisms beyond clinically recognized stroke and shared risk factors may link AF and cognitive impairment. One of the leading potential mechanisms is the occurrence of silent cerebral infarcts, which occur significantly more frequently than clinical stroke and are particularly common in patients with AF. 68, 69 Detection of cerebral ischaemic events on MRI is based on acute hyperintense lesions on DWI. Brain MRIs reveal evidence of silent cerebral infarcts in a significant percentage of patients with AF. 69 The incidence is related to specifications of MRI and depends on the definition applied. 70 Atrial fibrillation is associated with a more than two-fold increase in the risk of developing silent cerebral infarcts. 69 Although silent infarcts are not associated with clinically apparent acute neurologic deficits, data suggest a significant association between silent infarcts and the development of cognitive decline and dementia. 56, 71, 72 Silent infarcts in patients with AF are believed to be micro-embolic in origin and are identified as small, well-demarcated lesions, often in clusters, and are most prevalent in the frontal lobes. 56 The pattern of silent infarct distribution is similar to that seen in vascular dementia, in which most silent strokes affect frontal circuit components (frontal cortex, basal ganglia, and thalamus)
that play an important role in executive functioning. 73 Thus, the term "silent infarct" is probably a misnomer. Because of their small size and location away from speech and motor centres, these micro-injuries do not cause clinically apparent acute focal neurological deficits.
However, with the accumulation of silent infarcts and associated repetitive brain injuries over time, micro-injuries may contribute to the development of cognitive impairment. At least one study has specifically addressed the role of subclinical cerebrovascular disease as a mediator between AF and cognitive impairment. In a subset of stroke-free participants in the ARIC study who underwent repeat brain MRI after approximately 12 years, AF was associated with cognitive decline only in those patients who had developed incident silent cerebral infarcts. 74 There is a paucity of evidence regarding the effect of anticoagulation on silent cerebral infarcts and the risk of cognitive impairment.
One recent study addressed this issue by evaluating the time in therapeutic range (TTR) as an indicator of the effectiveness of warfarin anticoagulation in patients with AF. These investigators observed a consistent increase in the risk of dementia as the percentage of TTR decreased. 75 The association between warfarin therapy and dementia was "U"-shaped, with increased risk of dementia among patients with overexposure and underexposure to warfarin [i.e. supra-therapeutic and sub-therapeutic international normalized ratios (INRs)]. 75 This may be due to cumulative brain injury from cerebral microbleeds and silent infarcts, respectively. Recent observational data also suggest that delaying warfarin therapy in patients with AF and no history of dementia, including patients at low as well as high risk for stroke, significantly increases the risk for developing incident dementia. 12, 76 Whether the use of the NOACs will offer greater protection than warfarin in preventing AF-related cognitive impairment and dementia remains to be determined. The significantly lower intracranial haemorrhage and micro-haemorrhage rates, 77 Although both AF and dementia are diseases of aging, in two large observational studies the highest RR of dementia was observed in younger AF patients <70 years of age. 84, 85 A recent cross-sectional study indicated that in individuals with heart failure with reduced and preserved systolic ejection fraction, AF was associated with an adjusted higher odds of presence and severity of prevalent cognitive impairment. 86 (≥80 years) the relationship between AF and dementia seems to be mostly mediated by concomitant risk factors. 87 The relationship between AF and cognitive decline may occur through a variety of pathological mechanisms. Given the relationship between AF and stroke, vascular dementia may be an obvious contributor to cognitive decline, encompassing both multi-infarct dementia and SVD dementia. [80] [81] [82] [83] 88 The second form of dementia in AF patients is Alzheimer's disease, which is the most common type of dementia overall. Atrial fibrillation has been identified as a risk factor for Alzheimer's disease. 84, 89 Alzheimer's disease is the result of accumulation of abnormally folded beta-amyloid and tau proteins forming cerebral plaques which exert cytotoxic effects leading to cerebral atrophy. Interestingly, misfolded atrial natriuretic peptides may lead to development of amyloid fibrils and deposits in the atria of elderly patients with AF causing a specific atrial cardiomyopathy classified as EHRAS IVa. 90, 91 However, if AF and Alzheimer's disease share a common link with regards to protein misfolding and amyloidgenesis, it does not appear to be through the APOE e4 allele. 92 Other studies suggest that the occurrence of Alzheimer's disease is related to hypoperfusion, inflammation, oxidative stress, and endothelial dysfunction. [93] [94] [95] All these factors may be induced by several non-cardiac diseases resulting in an atrial cardiomyopathy which in turn, leads to AF 91 in the sense of both AF and Alzheimer's disease being the result of third confounding factors. Additionally, several circulating biomarkers of oxidative stress, inflammation, and endothelial dysfunction are elevated during AF. 91, 96, 97 These factors are also linked to cerebral SVD; therefore, AF may provide a specific milieu for non-stroke related cognitive decline and dementia. For example, hippocampal atrophy in AF patients may be mediated by altered cerebral perfusion due to irregular R-R intervals, abnormal or rapid heart rate, and reduced blood pressure caused by AF, since the hippocampus is one of the most perfusion-sensitive structures of the brain. 94, [98] [99] [100] [101] Interestingly, patients with AF had lower total brain volume when compared with those without AF, independent of cerebral emboli in a large cross-sectional study. 102 In addition, recently, AF was associated with a decrease in total cerebral blood flow and brain perfusion in an unselected elderly cohort. 103 These results may, at least in part, explain the association of AF with reduced relative brain volume and cognitive impairment.
A schematic overview of the various mechanisms, through which AF may lead to cognitive impairment is illustrated in Figure 1 .
A number of trials are currently examining, as the primary or secondary outcome, the effect of different therapies including anticoagulation and of different interventions on cognitive function in patients with AF. A non-exhaustive list of such studies is found in Table 8 .
The results of these studies will help to improve our understanding of the relationship between AF and cognitive function and provide us with more data for possible prevention of cognitive decline by treatment of AF.
It should also be noted that, conversely, impairment of cognitive function per se might have a negative impact on therapy adherence and medication intake 104, 105 and might thus adversely affect treatment effectiveness and outcome in patients with arrhythmias.
| Assessment of cognitive function in atrial fibrillation patients in clinical practice
Despite increasing awareness about the relationship between AF and cognitive decline, 74, 98, 106, 107 clinical guidelines for the management of AF do not specifically include assessment of cognitive function in the diagnostic work-up. With increasing prevalence of cognitive impairment in the elderly 108 and given that the highest RR of cognitive decline is in AF patients >70 years of age, healthcare professionals who treat AF patients should be able to diagnose, and assess risk factors for cognitive impairment appropriately.
Assessment of cognitive function should be multifaceted (see Table 3 ), and psychometric testing is just one component. Numerous validated tools are available to assess cognitive function, varying from brief screening tools, which take 1-8 minutes to complete among elderly patients, to more complex time-consuming neuropsychological batteries (see Table 4 ). Brief screening tools may be most applicable when cognitive impairment is suspected among AF patients, whereas more comprehensive assessments may be performed after appropriate referral to a geriatrician or neurologist.
Other factors determining the choice of test include the time available with the patient, the setting (office-based or inpatient), the patient's ability to speak English (some tools are not translated and/ or validated in other languages), and the purpose of the assessment 
| Prevention of cognitive dysfunction in atrial fibrillation patients
Since the precise mechanism(s) of cognitive disorders in patients with AF is not fully known, the optimal way to prevent cognitive dysfunction for a given patient remains to be established. Considering the mechanisms of cognitive impairment described in the sections above, several therapies may be considered (see "Recommendations"). Both disease states share common risk factors that include aging, smoking, hypertension, diabetes, sleep apnoea, physical inactivity, vascular disease, inflammation, and heart failure. There are no robust data to affirm that therapy for rhythm control with medication or "successful" AF catheter ablation can prevent cognition disorders in AF patients. Atrial fibrillation catheter ablation may not eliminate AF in the majority of patients, but rather attenuate overall AF burden. Follow-up data beyond 5 or 10 years are limited, and suggest that 2-5% of "successfully" ablated patients will have recurrences annually. [117] [118] [119] [120] Furthermore, many of these recurrences may be asymptomatic and the prognostic implication of asymptomatic episodes on both stroke risk and cognitive function is unknown. [121] [122] [123] Catheter ablation as a specific therapeutic approach to lower risk of stroke and dementia is discussed in the Catheter Ablation section.
In patients with persistent AF for whom which rhythm control is not pursued, atrioventricular (AV) node ablation with pacemaker implantation that restores a predictable R-R interval and heart rate has been shown, in a small study, to improve frontal and temporal blood flow and improve memory and learning. shown to be associated with cognitive deficits in 48% of such patients, when assessed prior to catheter ablation. 125 Whether an early catheter ablation of supraventricular arrhythmia would affect the cognitive status of such patients needs further investigation.
| Cognitive impairment after cardiac arrest 6.2.1 | Brain injury after non-fatal cardiac arrest
Cardiac arrest occurs in two different settings, in-hospital and outof-hospital, with completely different prognosis, for obvious reasons.
As cardiac arrests that occur in a hospital context are usually immediately attended, the primary focus of the study of brain injury after cardiac arrest has been among survivors of out-of-hospital cardiac arrest (OHCA). 126 In this setting, brain damage is caused by cerebral hypoperfusion and its severity depends on the time of such deficit 127 ; the proportion of cardiac arrest survivors who present with some degree of brain damage ranges from 35% to 100%. 128, 129 The working group of Chun-Lim and colleagues has delineated three scenarios that are clearly related to the duration of brain hypoperfusion:
(i) patients with early recovery of brain function without any sequelae, usually associated with opportune resuscitation and/or early recovery of consciousness (<3 days after OHCA); (ii) patients with extensive damage, associated with prolonged coma (>7 days after OHCA); and (iii) an intermediate group between those extremes. 130 They report that a coma duration of <3 days results in a better
quality of life at 3-and 12-month follow-up, and that the manifestation of severe cognitive impairment early on in recovery results in higher risk for permanent memory and motor impairment. while the mRS classifies patients on a 0-6 scale (0 = asymptomatic; 6 = deceased); CPC scores of 1-2 and mRS scores of 0-3 are considered favourable neurological outcomes. 134 These criteria are included as a reminder of the risk of neurological dysfunction among survivors of cardiac arrest.
| Memory impairment after cardiac arrest
In patients successfully treated for an OHCA in a rapid emergency response program, the long-term survival and quality of life are similar to age-and gender-matched controls. 135 However, if cognitive assessment is evaluated in detail, memory loss is prevalent. 136 Alexander et al 137 reported that among 30 selected patients (1 day of coma, with responsiveness after 24 hours but with remaining confusion for 7 days), only one-third of the sample suffered from motor impairment after the event, but the total population showed at least a mild degree of memory impairment. Torgersen et al 138 also
reported that even after therapeutic hypothermia, 52% of the patients who suffered cardiac arrest showed cognitive impairment, especially episodic memory dysfunction. This finding is not new, in 1996, Grubb et al 139 demonstrated in a population of 35 patients that up to 37% of the patients suffered chronic memory impairment after cardiac arrest, and that memory dysfunction was inversely proportional to the duration of the event.
Memory impairment after cardiac arrest does not seem to improve over time; a case-control study comparing OHCA patients with patients who suffered acute coronary syndrome without OHCA (controls) showed that memory impairment recorded at 3-month follow-up remained unchanged after 12 months, with just mild improvement of other functions. 130 Further, only 16% returned to work after the cardiac arrest whereas more than 94% of controls returned to work. 130 This study also evaluated quality of life among cardiac arrest survivors and controls; physical quality of life was not perceived as impaired in either group, however, the "cases" perceived a worse quality of life as a result of memory impairment. 
| Cardiac implantable electronic devices and cognitive dysfunction
Patients requiring cardiac implantable electronic devices (CIEDs) are generally older and as such may have associated cognitive dysfunction. It has also been shown that patients with severe bradycardia or high-grade AV block may show impaired cognitive function. [149] [150] [151] Bradycardia is also more common in patients treated for dementia with cholinesterase inhibitor drugs (adjusted HR 1.4, 95% CI: 1.1-1.6) and increases the risk of syncope, CIED need, and falls. 152 A retrospective study showed that patients with cognitive dysfunction were more likely than those without cognitive deficits to be implanted with a pacemaker, even after adjusting for clinical risk factors. 153 Treatment of both permanent or transient bradycardia with CIEDs has been shown to improve cognition in a number of small trials. 150, 151, 154 Although it may be inferred that patients with cognitive impairment and standard device indications may be at increased risk for device complications, this was not demonstrated in a study by Jama et al 155 However, the survival was lower than in matched controls suggesting that these patients may have more co-morbidities. A small study suggested that the increase in cerebral blood flow after pacemaker implantation for symptomatic bradycardia resulted in improvement in cognitive function. 151 Another small study showed that the improvement was, however, not significant over a 6-12 months follow-up after pacemaker implantation. 150 Ventricular pacing may result in impaired haemodynamics and has been associated with AF, which itself has been associated with multi-infarct dementia. Ventricular pacing was noted to show a trend towards a detrimental effect on the visual memory score. 156 It is well known that CIED may have psychological side effects; this is particularly true for ICD and especially shock therapy. 157, 158 Apart from this psychological effect, there may be a direct effect on cognitive function.
Implantable cardioverter-defibrillator implantation with defibrillation testing has been reported to initially result in cognitive dysfunction in 31-39% of patients, as determined by neuropsychological testing before and after ICD implantation in 52 patients, however most patients improve within a year. 159 Another study in 115 ICD patients observed that cognitive function in memory was poor at baseline and decreased over 12 months post-ICD implantation. 160 In a small
Polish study of 51 patients with primary prevention ICDs, seven patients who received ICD shocks for ventricular fibrillation scored worse in neuropsychological measurements compared with patients without such shocks, suggesting greater cognitive impairment, 161 which could be multifactorial. However, further studies are needed to demonstrate whether shock or prevention of ventricular fibrillation will prevent decline in cognitive function.
In contrast, there are several reports that cardiac resynchronization therapy may be associated with neurocognitive functional improvement. [162] [163] [164] [165] [166] An early systematic review of three studies reported improvements in executive functioning and attention.
| Catheter ablation
With mounting evidence to suggest an association between arrhythmias and cognitive decline and dementia, treatment of these arrhythmias has been considered as an option to lower risk of cognitive decline. As antiarrhythmic drug therapies have variable efficacy and are associated with many side effects, and medications can directly influence quality of life, mood, and function, 167 catheter ablation is often employed as a durable non-pharmacological option.
The majority of evidence that catheter ablation may impact cognition is derived from observational studies of AF management. Outcomes in a consecutive series of 4212 patients who underwent AF ablation were compared (1:4) with 16 848 age/gender-matched controls with AF (no ablation) and 16 848 age/gender-matched controls without AF. In this analysis, stroke outcomes of patients with AF, and an ablation, were better than patients with AF and no ablation, but similar to patients without AF. 168 Similarly, long-term outcomes of cognition were better in AF ablation patients compared with AF patients who did not undergo ablation, including lower rates of Alzheimer's, senile, and vascular dementia. Cognitive outcomes between those patients that received an ablation were similar to patients without a history of AF, including all subtypes of dementia. In patients with atrial flutter stroke rates post-ablation are significantly lower compared with AF patients treated with ablation. 169 However, as these were not RCTs, better outcomes could have been related to selection bias rather than impact of ablation.
Dementia has not been a traditional endpoint in observational studies of outcomes after AF ablation. However, stroke and TIA are commonly reported endpoints. Long-term cognitive deficits are common after stroke with up to 10% of patients developing dementia after their first stroke with an incidence that increases to 30-40% with recurrent stroke. 23 In a propensity-matched study of 969 consecutive AF ablation patients with a CHA 2 DS 2 -VASc score ≥2, AF ablation was associated with a long-term reduced risk of stroke (HR 0.62, 95% CI: 0.47-0.82) and TIA (HR 0.47, 95% CI: 0.20-0.78). 170 In a separate observational study, AF ablation was associated with lower rates of stroke/TIA compared with AF patients not treated with ablation across all age and CHADS 2 strata including patients considered at high risk for stroke and patients with prior stroke.
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In this study, stroke rates in all groups increased with higher CHADS 2 scores, including non-AF patients, consistent with the influence of systemic risk factors on stroke risk beyond that of AF.
Catheter ablation of all arrhythmias has peri-procedural risks that may have long-term significant consequences with regard to cognition and dementia risk. Procedural risk with all cardiac left sided procedures may impact long-term cognition due to the presence of peri-procedural thrombus, atheroemboli, cerebral hypoperfusion, sheath and wire manipulation and management, and anaesthesia. In patients that undergo right sided cardiac procedures the risk is anticipated to be lower although paradoxical thromboembolism can occur in the presence of a septal defect. 169 The risk of stroke during left atrial catheter ablation is estimated at approximately 0.5-1%. 121 However asymptomatic or subclinical ischaemic lesions develop in up to 41% of AF ablation patients with an incidence that varies with anticoagulation approach, ablation tool used, and cranial scan protocol. 121, 122, 172, 173 In addition, when peri-procedural transcranial Doppler analysis is used during AF ablation to monitor for emboli, sheath manipulation, removal and insertion of tools, and using of multiple tools within the left atrium are significantly associated with microembolic events. 174 The risk of these lesions is higher (up to 63%) during ventricular arrhythmia ablation with retro-aortic access and long sheaths in the aorta being unique risk factors. 175 To put these incidences in context with other cardiovascular procedures, the estimated incidence of new brain lesions has been reported to be 8-18% after AF ablation, 11-17% after coronary
angiography or percutaneous coronary intervention, 16-51% after coronary artery bypass graft, 38-47% after surgical aortic valve replacement, 68-91% after transaortic valve implantation, 4-34% after carotid endarterectomy, 15-67% after carotid artery stenting, 11-20% after cerebral angiography, and 10-64% after endovascular aneurysm procedures. 182 Procedural stroke, typically related to air embolism, has also been reported with the Watchman device in the PROTECT trial, although impact on long-term cognition is unknown. 183, 184 However, any long-term impact on cognition has not been reported.
| CURRENT KNOWLEDGE GAPS, FUTURE DIRECTIONS, AND AREAS FOR RESEARCH
Global management of dementia syndromes has been recently set as a public health priority, and the World Health Organization has prioritized seven research domains to reduce the global burden of Other expert groups have also provided recommendations for further progress and improvements in dementia-related research 186 and highlighted knowledge gaps in cardiovascular care of the elderly, including those with cognitive impairment. 187 Declining incidence and age-specific prevalence of dementia in high-income countries [188] [189] [190] [191] implies that dementia risk is modifiable, likely through improved management of cardiovascular risk factors 192 and psychosocial factors. 186, [193] [194] [195] Although dementia-prevention RCTs failed to confirm many signals from observational studies, those
RCTs highlighted some key methodological issues to be considered in contemporary trials (Table 9 ).
Elderly patients with cognitive impairment commonly have mixed pathologies, including cardiovascular disease (e.g. AF and heart failure) 80, 85, [196] [197] [198] aspirin. 113 In retrospective observational studies the risk of dementia increased with poor management of VKA (a low TTR), 75, 112 whilst NOAC use was associated with lower risk for dementia compared with warfarin. 114 Observational data on AF patients diagnosed with dementia consistently shows significant VKA underuse or discontinuation 62 even post-stroke, 199 despite similar VKA-related bleeding risk irrespective of the cognitive status. Large prospective studies with pre-specified cognitive outcomes are needed to identify optimal thrombo-prophylactic strategies for AF patients with cognitive Low levels of vitamin D and B 12 , and folate increase risk, but the value of supplementation remains unproven. Calcium supplementation in women has been associated with increased dementia risk. [200] [201] [202] The value of modulating cognitive function based on educational interventions is uncertain.
Weight loss in obesity | 117 impairment/dementia. Importantly, the effects of early AF treatment or primary AF prevention on cognitive deterioration in patients at risk for both conditions remain to be elucidated.
Elderly patients and those with cognitive impairment/dementia were generally under-represented in catheter ablation and CIED (i.e. ICD and cardiac resynchronization therapy) trials. Studies are needed to better define the risks and benefits of cardiac arrhythmias ablation or CIED implantation, long-term effects of these interventions on cognitive status and optimal strategies for shared decision-making and end-of-life decisions in these patients (Table 9 ).
| RECOMME NDATIONS
Interventions that can be considered for prevention of cognitive dysfunction in AF patients are summarized in Table 10 . The writing committee reached consensus on recommendations summarized in Table 11 .
R E F E R E N C E S T A B L E 1 1 Recommendations for measures to prevent cognitive dysfunction in AF patients
Preventive measures of cognitive dysfunction in patients with AF Class References
Appropriate anticoagulation in patients with AF and stroke risk factors should be applied for the prevention of cognitive dysfunction
107, 111
Consider NOAC instead of VKA when using oral anticoagulation for the prevention of stroke in AF, which may have a beneficial effect on subsequent cognitive disorders
107, 114
In patients with AF managed with long-term VKA, a high anticoagulation time in therapeutic range may be beneficial for optimal prevention of new-onset dementia
75, 107
General health measures (prevention of smoking, hypertension, obesity and diabetes, sleep apnoea, and appropriate control of all risk factors) may reduce the concomitant risks of AF (new onset or recurrences) and stroke, with a putative benefit on cognitive function 
